7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Checkmate Pharmaceuticals, Inc
(NASDAQ:CMPI) 

CMPI stock logo

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanom...

Founded: 2015
Full Time Employees: 25 (May 2021)
CEO: Barry A. Labinger  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Checkmate Pharmaceuticals Op Cashflow Per Share ttm
202208 202209 202210 202211 202212 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -5.62-4.82-4.01-3.21-2.41-1.61-0.80
Checkmate Pharmaceuticals Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -5.62-4.82-4.01-3.21-2.41-1.61-0.80
Checkmate Pharmaceuticals Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.761.512.273.033.794.545.3
Checkmate Pharmaceuticals (GAAP) P/E ratio ttm
202208 202209 202210 202211 202212 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -7.78-6.67-5.55-4.44-3.33-2.22-1.110
Checkmate Pharmaceuticals P/B ratio ttm
202208 202209 202210 202211 202212 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.591.181.772.362.953.544.13
No extra charts and metrics for this ticker.